TIDMBYOT
RNS Number : 9202R
Byotrol PLC
11 July 2022
Byotrol plc ("Byotrol" or the "Company")
Post Close Trading Update
Notice of Results
Byotrol plc (AIM: BYOT), the infection prevention technology
company, today provides an update on trading for the year ended 31
March 2022. Subject to audit, it is expected that the results will
be in line with the trading updates made ahead of the year-end
including:
-- Sales of GBP6.3m, comprising GBP5.2m from product sales and
GBP1.1m from IP sales and royalties;
-- Positive Adjusted EBITDA, before exceptional items;
-- Cash at year end of GBP1.1m.
The Board is pleased to report that for the first time we
include in IP revenue a contribution from Solvay for Byotrol's
on-going participation in Solvay's sales of Actizone 24 hour
surface sanitiser. As previously announced, this is a small
quantum, but a very encouraging first financial step.
Post-period end
Since the year end, the Company has closed two significant new
IP agreements.
1. a multi-year, three-way, exclusive agreement between the
Company, our US licensee Integrated Resources International (IRI),
and a significant US distribution company ("USCo"), to sub-register
with the US EPA and then sell the Byotrol24 surface sanitiser under
USCo branding into US Professional markets. Should formal
registration be achieved - expected within 12 months - sales by IRI
to USCo will accrue additional royalties to Byotrol. The Company
expects to have further clarity on this when it reports its audited
results for the year.
2. a seven year license in alcohol-free hand sanitisers with
Rentokil Initial Plc . This is a non-exclusive license of rights to
our proprietary hand sanitising formulation for distribution by
Rentokil under its own brand into serviced washrooms, predominantly
in the UK and Europe
Byotrol expects to release audited final results for the full
year to 31 March 2022 before the end of next month.
David Traynor, CEO of Byotrol plc, commented:
"We are pleased to confirm that our results for the past year
will meet expectations as described in our trading update of early
March.
We are also pleased to announce further progress in licensing
and IP, with two new agreements with best-in-class names in their
respective markets, and confirmation that Solvay's Actizone24
product is now gaining commercial traction.
Underlying market trends remain very favourable for our
long-term growth. We look forward to providing a further update on
product and IP sales with the release of our final audited results,
which is expected in August."
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
For further information, visit www.byotrolplc.com , follow on
twitter @byotrol, or contact
Byotrol plc
David Traynor - Chief Executive Officer
Chris Sedwell - Chief Financial Officer 01925 742 000
finnCap
Geoff Nash/ James Thompson - Corporate Finance
Richard Chambers - ECM - 020 7220 0500
Flagstaff Strategic and Investor Communications 020 7129
1474
Tim Thomson/Andrea Seymour/Fergus Melon
byotrol@flagstaffcomms.com
Notes to Editors:
Byotrol plc (BYOT.L), quoted on AIM, is a leading infection
prevention and control company, operating globally in the animal
health, human health, facilities management, and consumer
sectors.
Byotrol develops unique antimicrobial technologies for use on
surfaces, skin and instruments, which it then commercialises
through market-leading distribution partners in each sector.
Byotrol's antimicrobial technologies can be licensed for use in
leading brands, to significantly improve their product claims,
while reassuring consumers and end-users of their efficacy and
quality.
Founded in 2005, the Company develops technologies and products
with the aim of providing easier, safer and cleaner lives for
everyone.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTMZGGNNRZGZZM
(END) Dow Jones Newswires
July 11, 2022 02:00 ET (06:00 GMT)
Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Byotrol (LSE:BYOT)
Storico
Da Lug 2023 a Lug 2024